(Q39911338)

15 September 2017

title

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells (English)

1 reference

15 September 2017

main subject

chronic myeloid leukemia

0 references

bosutinib

1 reference

ChEBI release 2020-05-28

1 reference

12

1 reference

15 September 2017

O Hantschel

4

0 references

author name string

L L Remsing Rix

1

1 reference

15 September 2017

U Rix

2

1 reference

15 September 2017

J Colinge

3

1 reference

15 September 2017

K L Bennett

5

1 reference

15 September 2017

T Stranzl

6

1 reference

15 September 2017

A Müller

7

1 reference

15 September 2017

C Baumgartner

8

1 reference

15 September 2017

P Valent

9

1 reference

15 September 2017

M Augustin

10

1 reference

15 September 2017

J H Till

11

1 reference

15 September 2017

publication date

27 November 2008

1 reference

15 September 2017

1 reference

15 September 2017

volume

23

1 reference

15 September 2017

issue

3

1 reference

15 September 2017

page(s)

477-485

1 reference

Current and emerging treatment options in chronic myeloid leukemia

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Flying under the radar: the new wave of BCR-ABL inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

AXL is a potential target for therapeutic intervention in breast cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Biosignaling of mammalian Ste20-related kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

The GCK II and III subfamilies of the STE20 group kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

The dark side of the NGF family: neurotrophins in neoplasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Cytogenetics of the chronic myeloid leukemia-derived cell line K562: karyotype clarification by multicolor fluorescence in situ hybridization, comparative genomic hybridization, and locus-specific fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

The tyrosine kinase FES is an essential effector of KITD816V proliferation signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Circumventing Resistance to Kinase-Inhibitor Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Imatinib as a paradigm of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2008.334

1 reference

Dimensions Publication ID

15 September 2017

1043735889

0 references

1 reference